Cardiovascular risk assessment scores for people with diabetes: a systematic review

被引:122
作者
Chamnan, P. [1 ]
Simmons, R. K. [1 ]
Sharp, S. J. [1 ]
Griffin, S. J. [1 ]
Wareham, N. J. [1 ]
机构
[1] Addenbrookes Hosp, Inst Metab Sci, MRC, Epidemiol Unit, Cambridge CB2 0QQ, England
基金
英国医学研究理事会;
关键词
Cardiovascular disease; Diabetes; Prediction; Risk score; Systematic review; CORONARY-HEART-DISEASE; PLACEBO-CONTROLLED TRIAL; C-REACTIVE PROTEIN; PRIMARY PREVENTION; MULTIFACTORIAL INTERVENTION; PREDICTIVE ABILITY; PHYSICAL-ACTIVITY; NORFOLK COHORT; EPIC-NORFOLK; ROC CURVE;
D O I
10.1007/s00125-009-1454-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
People with type 2 diabetes have an increased risk of cardiovascular disease (CVD). Multivariate cardiovascular risk scores have been used in many countries to identify individuals who are at high risk of CVD. These risk scores include those originally developed in individuals with diabetes and those developed in a general population. This article reviews the published evidence for the performance of CVD risk scores in diabetic patients by: (1) examining the overall rationale for using risk scores; (2) systematically reviewing the literature on available scores; and (3) exploring methodological issues surrounding the development, validation and comparison of risk scores. The predictive performance of cardiovascular risk scores varies substantially between different populations. There is little evidence to suggest that risk scores developed in individuals with diabetes estimate cardiovascular risk more accurately than those developed in the general population. The inconsistency in the methods used in evaluation studies makes it difficult to compare and summarise the predictive ability of risk scores. Overall, CVD risk scores rank individuals reasonably accurately and are therefore useful in the management of diabetes with regard to targeting therapy to patients at highest risk. However, due to the uncertainty in estimation of true risk, care is needed when using scores to communicate absolute CVD risk to individuals.
引用
收藏
页码:2001 / 2014
页数:14
相关论文
共 60 条
[1]   CARDIOVASCULAR-DISEASE RISK PROFILES [J].
ANDERSON, KM ;
ODELL, PM ;
WILSON, PWF ;
KANNEL, WB .
AMERICAN HEART JOURNAL, 1991, 121 (01) :293-298
[2]   Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study [J].
Assmann, G ;
Cullen, P ;
Schulte, H .
CIRCULATION, 2002, 105 (03) :310-315
[3]   Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor.: The DECODE Study [J].
Balkau, B ;
Hu, G ;
Qiao, Q ;
Tuomilehto, J ;
Borch-Johnsen, K ;
Pyörälä, K .
DIABETOLOGIA, 2004, 47 (12) :2118-2128
[4]   Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review [J].
Brindle, P. ;
Beswick, A. ;
Fahey, T. ;
Ebrahim, S. .
HEART, 2006, 92 (12) :1752-1759
[5]   Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study [J].
Brindle, P ;
Emberson, J ;
Lampe, F ;
Walker, M ;
Whincup, P ;
Fahey, T ;
Ebrahim, S .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7426) :1267-1270A
[6]   How do people with Type 2 diabetes perceive and respond to cardiovascular risk? [J].
Carroll, C ;
Naylor, E ;
Marsden, P ;
Dornan, T .
DIABETIC MEDICINE, 2003, 20 (05) :355-360
[7]   Risk Prediction of Cardiovascular Disease in Type 2 Diabetes [J].
Cederholm, Jan ;
Eeg-Olofsson, Katarina ;
Eliasson, Bjoern ;
Zethelius, Bjoern ;
Nilsson, Peter M. ;
Gudbjornsdottir, Soffia .
DIABETES CARE, 2008, 31 (10) :2038-2043
[8]   Estimation of time-dependent area under the ROC curve for long-term risk prediction [J].
Chambless, Lloyd E. ;
Diao, Guoqing .
STATISTICS IN MEDICINE, 2006, 25 (20) :3474-3486
[9]   Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes [J].
Coleman, Ruth L. ;
Stevens, Richard J. ;
Retnakaran, Ravi ;
Holman, Rury R. .
DIABETES CARE, 2007, 30 (05) :1292-1294
[10]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696